← Yipinhong Pharmaceutical overview

Yipinhong Pharmaceutical vs Sichuan Kelun Pharmaceutical: why the prices moved differently

Weekly · monthly · quarterly news summaries, side by side in time

Yipinhong Pharmaceutical Co Ltd Class A (300723.CS)

Q3 2026
▲3▼1

Yipinhong's pipeline expands with new drug approvals and GLP-1 clinical progress

  • New drug approvals broaden product portfolio Yipinhong received registration certificates for Benzbromarone Tablets, Sertraline Hydrochloride Oral Solution, and Eltrombopag Olamine Dry Suspension. These add new products to its chronic disease lineup, potentially boosting future sales and diversifying revenue, though each carries launch and sales execution risk.

    Multiple new product approvals are a key positive driver for future revenue growth.

  • Innovative drug pipeline advances with clinical milestones Yipinhong's innovative drug APH04935 (a GLP-1 receptor agonist for weight management) received Chinese clinical trial approval and later FDA approval to start US trials. Another innovative drug, APH03867 for gout with hyperuricemia, also got clinical trial approval. These milestones signal progress in high-value areas.

    Clinical progress in innovative drugs like GLP-1 and gout treatments supports long-term growth prospects.

  • National procurement selection may boost sales Two Yipinhong drugs were tentatively selected for the 12th National Centralized Drug Procurement. While current revenue from these drugs is minimal, selection can significantly increase sales volumes through government-backed purchasing, though at lower prices.

    Procurement wins can drive volume growth and market access for the selected drugs.

  • Interim results show revenue decline and margin pressure Yipinhong's 2026 interim report revealed a 15.77% year-on-year revenue drop and an 8.64 percentage point sequential decline in gross margin. Although net profit was 485 million yuan, the top-line weakness and margin erosion weigh on investor sentiment.

    Financial performance is a key counterweight to the positive pipeline news.

August 2026
▲3▼1

Yipinhong's pipeline expands with new drug approvals and GLP-1 clinical progress

  • New drug approvals broaden product portfolio Yipinhong received registration certificates for Benzbromarone Tablets, Sertraline Hydrochloride Oral Solution, and Eltrombopag Olamine Dry Suspension. These add new products to its chronic disease lineup, potentially boosting future sales and diversifying revenue, though each carries launch and sales execution risk.

    Multiple new product approvals are a key positive driver for future revenue growth.

  • Innovative drug pipeline advances with clinical milestones Yipinhong's innovative drug APH04935 (a GLP-1 receptor agonist for weight management) received Chinese clinical trial approval and later FDA approval to start US trials. Another innovative drug, APH03867 for gout with hyperuricemia, also got clinical trial approval. These milestones signal progress in high-value areas.

    Clinical progress in innovative drugs like GLP-1 and gout treatments supports long-term growth prospects.

  • National procurement selection may boost sales Two Yipinhong drugs were tentatively selected for the 12th National Centralized Drug Procurement. While current revenue from these drugs is minimal, selection can significantly increase sales volumes through government-backed purchasing, though at lower prices.

    Procurement wins can drive volume growth and market access for the selected drugs.

  • Interim results show revenue decline and margin pressure Yipinhong's 2026 interim report revealed a 15.77% year-on-year revenue drop and an 8.64 percentage point sequential decline in gross margin. Although net profit was 485 million yuan, the top-line weakness and margin erosion weigh on investor sentiment.

    Financial performance is a key counterweight to the positive pipeline news.

Latest
▲3▼1

Yipinhong's pipeline expands with new drug approvals and GLP-1 clinical progress

  • New drug approvals broaden product portfolio Yipinhong received registration certificates for Benzbromarone Tablets, Sertraline Hydrochloride Oral Solution, and Eltrombopag Olamine Dry Suspension. These add new products to its chronic disease lineup, potentially boosting future sales and diversifying revenue, though each carries launch and sales execution risk.

    Multiple new product approvals are a key positive driver for future revenue growth.

  • Innovative drug pipeline advances with clinical milestones Yipinhong's innovative drug APH04935 (a GLP-1 receptor agonist for weight management) received Chinese clinical trial approval and later FDA approval to start US trials. Another innovative drug, APH03867 for gout with hyperuricemia, also got clinical trial approval. These milestones signal progress in high-value areas.

    Clinical progress in innovative drugs like GLP-1 and gout treatments supports long-term growth prospects.

  • National procurement selection may boost sales Two Yipinhong drugs were tentatively selected for the 12th National Centralized Drug Procurement. While current revenue from these drugs is minimal, selection can significantly increase sales volumes through government-backed purchasing, though at lower prices.

    Procurement wins can drive volume growth and market access for the selected drugs.

  • Interim results show revenue decline and margin pressure Yipinhong's 2026 interim report revealed a 15.77% year-on-year revenue drop and an 8.64 percentage point sequential decline in gross margin. Although net profit was 485 million yuan, the top-line weakness and margin erosion weigh on investor sentiment.

    Financial performance is a key counterweight to the positive pipeline news.

Sichuan Kelun Pharmaceutical Co Ltd (002422.CS)

Q3 2026
▲3▼1

Kelun's profit rises on drug wins and buybacks, but bribery claim and pledges weigh

  • New ADC drug enters clinical trials A Kelun subsidiary won Chinese approval to start human testing of SKB565, a new dual-payload ADC for advanced solid tumors. It is the first of its kind from Kelun Biotech, and success could add a valuable future growth engine, though it is years from sales.

    Shows pipeline progress that can lift long-term growth expectations for the stock.

  • National procurement wins boost sales outlook Kelun and its units won tentative selection for more than ten products in China's 12th national bulk-buy drug round, including heart and cancer medicines. Winning means guaranteed hospital sales volumes, supporting revenue even if prices are lower.

    Directly increases expected product demand and market share, a core earnings driver.

  • Profit grows and dividend plus buyback support stock First-half net profit rose 12.7% to 1.128 billion yuan, with second-quarter profit up 48% from the prior quarter, despite slightly lower revenue. The company also plans a cash dividend and has been buying back shares, signaling confidence and returning cash to holders.

    Earnings growth and shareholder returns are the main fundamental supports for the share price.

  • Bribery claim and owner pledges create risk A whistleblower letter alleged commercial bribery tied to a key Kelun drug; the subsidiary denies it and threatens legal action. Separately, controlling shareholder Liu Gexin added to pledged shares for personal funding. Both raise uncertainty and could pressure the stock if they worsen.

    These are the main counterweights that could hurt sentiment and valuation.

September 2026
▲3▼1

Kelun's profit rises on drug wins and buybacks, but bribery claim and pledges weigh

  • New ADC drug enters clinical trials A Kelun subsidiary won Chinese approval to start human testing of SKB565, a new dual-payload ADC for advanced solid tumors. It is the first of its kind from Kelun Biotech, and success could add a valuable future growth engine, though it is years from sales.

    Shows pipeline progress that can lift long-term growth expectations for the stock.

  • National procurement wins boost sales outlook Kelun and its units won tentative selection for more than ten products in China's 12th national bulk-buy drug round, including heart and cancer medicines. Winning means guaranteed hospital sales volumes, supporting revenue even if prices are lower.

    Directly increases expected product demand and market share, a core earnings driver.

  • Profit grows and dividend plus buyback support stock First-half net profit rose 12.7% to 1.128 billion yuan, with second-quarter profit up 48% from the prior quarter, despite slightly lower revenue. The company also plans a cash dividend and has been buying back shares, signaling confidence and returning cash to holders.

    Earnings growth and shareholder returns are the main fundamental supports for the share price.

  • Bribery claim and owner pledges create risk A whistleblower letter alleged commercial bribery tied to a key Kelun drug; the subsidiary denies it and threatens legal action. Separately, controlling shareholder Liu Gexin added to pledged shares for personal funding. Both raise uncertainty and could pressure the stock if they worsen.

    These are the main counterweights that could hurt sentiment and valuation.

Latest
▲3▼1

Kelun's profit rises on drug wins and buybacks, but bribery claim and pledges weigh

  • New ADC drug enters clinical trials A Kelun subsidiary won Chinese approval to start human testing of SKB565, a new dual-payload ADC for advanced solid tumors. It is the first of its kind from Kelun Biotech, and success could add a valuable future growth engine, though it is years from sales.

    Shows pipeline progress that can lift long-term growth expectations for the stock.

  • National procurement wins boost sales outlook Kelun and its units won tentative selection for more than ten products in China's 12th national bulk-buy drug round, including heart and cancer medicines. Winning means guaranteed hospital sales volumes, supporting revenue even if prices are lower.

    Directly increases expected product demand and market share, a core earnings driver.

  • Profit grows and dividend plus buyback support stock First-half net profit rose 12.7% to 1.128 billion yuan, with second-quarter profit up 48% from the prior quarter, despite slightly lower revenue. The company also plans a cash dividend and has been buying back shares, signaling confidence and returning cash to holders.

    Earnings growth and shareholder returns are the main fundamental supports for the share price.

  • Bribery claim and owner pledges create risk A whistleblower letter alleged commercial bribery tied to a key Kelun drug; the subsidiary denies it and threatens legal action. Separately, controlling shareholder Liu Gexin added to pledged shares for personal funding. Both raise uncertainty and could pressure the stock if they worsen.

    These are the main counterweights that could hurt sentiment and valuation.